Drug Profile
18F-fluorothymidine - Merck
Alternative Names: 18F-FLT (3'-deoxy-3'[18F]-fluorothymidine) - Merck; 18F-FLT - Merck; 18F-FLT-PET - MerckLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 27 Dec 2011 Merck completes a phase II trial in Breast cancer (diagnosis) in USA and South Korea (NCT01015131)
- 02 Jul 2011 Merck completes enrolment in its phase II trial for Breast cancer (diagnosis) in USA and South Korea (NCT01015131)